Pregnancy induced hypertension is one of the leading medical disorder of pregnancy and contributes significantly to poor maternal and perinatal outcome. The early detection and effective management play a beneficial role in the outcome of pregnancy, both for the mother and the baby. Incidence of Pre-eclampsia is 3-6% of all pregnancies and 1.5 to 2 times higher risk in primigravida. Materials and Methods: This study was hospital based observational prospective study from September 2020 to August 2022. Total 150 pregnant women included in the study and fetomaternal outcome were noted and statistical analysis done using SPSS-20. Results: Majority of patients were in age group 21-25 years in both the groups i.e. 44% in study group and 46.7 % in control group. In study group around 58.7% were preterm deliveries. In our study in group A with deranged biomarkers and group B with normal biomarkers, developed abruption placenta in 26.7 v/s 2.7%, eclampsia in 18.7% v/s 1.3%, HELLP syndrome in 8% v/s 0%, ARF in 4% v/s0% respectively. In our study perinatal complications developed in group A and group B were IUGR (20% v/s 8%), fetal distress(37.3% v/s 20%), NICU admission(49.3% v/s 29.3%), MSL (12% v/s 20%) and IUD (9.3% v/s 1.3%) respectively. Conclusion: Hypertensive disorders of pregnancy with deranged hepatic biomarkers are correlated with more adverse maternal and perinatal complications compared to normal hepatic biomarkers. Such cases require more frequent antenatal check-ups with serial ultrasonography.